Clinical Trial Update: Mepolizumab in Episodic Angioedema With Eosinophilia [Phase 2]

View source ↗

Summary

Phase 2 trial exploring mepolizumab for episodic angioedema with eosinophilia; study terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema
• Eosinophilia

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Eosinophilia, Angioedema | Phase 2 | Status: TERMINATED | Results posted: 2024-04-16